Olverembatinib
- CAS No.
- 1257628-77-5
- Chemical Name:
- Olverembatinib
- Synonyms
- GZD-824;GZD824;GZD8824;GZD 824;GZD-824 Free;Olverembatinib;GZD 824 USP/EP/BP;GZD824;GZD-824;GZD 824;Olverembatinib (GZD824);GZD-824; GZD 824;BENZAMIDE
- CBNumber:
- CB82666626
- Molecular Formula:
- C29H27F3N6O
- Molecular Weight:
- 532.56
- MDL Number:
- MFCD26142930
- MOL File:
- 1257628-77-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| GZD-824 ≥98% | 21508 | 1mg | $36 |
| GZD-824 ≥98% | 21508 | 5mg | $153 |
| GZD-824 ≥98% | 21508 | 10mg | $268 |
| GZD-824 ≥98% | 21508 | 25mg | $502 |
| GZD-824 ≥98% | 21508 | 1mg | $32 |
| More product size | |||
| Boiling point | 630.4±55.0 °C(Predicted) |
|---|---|
| Density | 1.39±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO : ≥ 100 mg/mL (187.77 mM) |
| form | A crystalline solid |
| pka | 9.04±0.40(Predicted) |
| color | Off-white to yellow |
| FDA UNII | KV1M7Q3CBP |
Olverembatinib price More Price(82)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 21508 | GZD-824 ≥98% | 1257628-77-5 | 1mg | $36 | 2026-04-30 | Buy |
| Cayman Chemical | 21508 | GZD-824 ≥98% | 1257628-77-5 | 5mg | $153 | 2026-04-30 | Buy |
| Cayman Chemical | 21508 | GZD-824 ≥98% | 1257628-77-5 | 10mg | $268 | 2026-04-30 | Buy |
| Cayman Chemical | 21508 | GZD-824 ≥98% | 1257628-77-5 | 25mg | $502 | 2026-04-30 | Buy |
| Cayman Chemical | 21508 | GZD-824 ≥98% | 1257628-77-5 | 1mg | $32 | 2024-03-01 | Buy |
Olverembatinib Chemical Properties,Uses,Production
Description
GZD-824 is an orally available inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants including T315I (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively). It has been shown to suppress the proliferation of Bcr/Abl-positive K562 and Ku812 human chronic myelogenous leukemia cells (IC50s = 0.2 and 0.13 nM, respectively) and induce tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl.
Uses
GZD824 is a orally bioavailable inhibitor that targets phosphorylated and non-phosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) kinases. It is a COVID19-related research product.
Definition
GZD 824 (Olverembatinib), another third-generation BCR-ABL tyrosine kinase inhibitor (TKI), was approved in 2021 in China for patients with T315I positive chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP). Like ponatinib, olverembatinib inhibits multikinases, including B-RAF, DDR1, FGFR, Flt3, KIT, PDGFRα/β, RET, and SRC.
Application
Olverembatinib is able to inhibit wild-type BCR-ABL1 kinase and a wide range of related mutants, including the T315I mutant, which makes it a potential treatment for TKI-resistant CML patients. In addition, Olverembatinib is also being studied for the treatment of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and solid tumors.
General Description
Class: non-receptor tyrosine kinase
Treatment: CML
Elimination half-life = 17.5–36.5 h
Synthesis
In a recent patent, the synthesis of olverembatinib began with a Sonogashira coupling reaction of commercially available alkyne 24.1 with pyridinium bromide 24.2 to afford ester 24.3 in 98% yield. The N-Boc group of carbonate 24.3 was cleaved by refluxing in a mixture of MeOH and water to afford pyrazole 24.4 in 91% yield. Finally, potassium tert-butoxide-mediated amide formation with aniline 24.5 afforded olverembatinib (24) in 88% yield.
target
BCR-ABL
References
[1] XIAOMEI REN. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region–Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib[J]. Journal of Medicinal Chemistry, 2013, 56 3: 879-894. DOI: 10.1021/jm301581y
Olverembatinib Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Nanjing ChemLin Chemical Industry Co., Ltd. | 025-83697070 | product@chemlin.com.cn | CHINA | 3009 | 60 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| TianYuan Pharmaceutical CO.,LTD | +86-755-23284190 13684996853 | sales@tianpharm.com | CHINA | 304 | 58 |
| Accela ChemBio Inc. | +1-858-6993322 +86-18019713315 | info@accelachem.com | United States | 21193 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32466 | 58 |
| Career Henan Chemica Co | +86-0371-86658258 +86-13203830695 | laboratory@coreychem.com | China | 30224 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | 1059@dideu.com | China | 29093 | 58 |
| Hefei Hirisun Pharmatech Co., Ltd | +8615056975894 | shawn@hirisunpharm.com | CHINA | 9911 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 | sales@invivochem.cn | United States | 6391 | 58 |
View Lastest Price from Olverembatinib manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Olverembatinib
1257628-77-5
|
$30.00-61.00 | 98.64% | 10g | TargetMol Chemicals Inc. | ||
 |
2026-07-25 | Olverembatinib
1257628-77-5
|
1kg | 98% | 1000kgs | Shaanxi Dideu New Materials Co. Ltd |
-
- Olverembatinib
1257628-77-5
- $30.00-61.00
- 98.64%
- TargetMol Chemicals Inc.
-
- Olverembatinib
1257628-77-5
- $0.00
- 98%
- Shaanxi Dideu New Materials Co. Ltd
